Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum

BACKGROUND: Since miltefosine monotherapy against visceral leishmaniasis (VL) caused by Leishmania donovani has been discontinued in the Indian subcontinent due to an increase in the number of treatment failures, single dose liposomal amphotericin B is now advocated as a treatment option of choice....

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrickx, Sarah, Van den Kerkhof, Magali, Mabille, Dorien, Cos, Paul, Delputte, Peter, Maes, Louis, Caljon, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444850/
https://www.ncbi.nlm.nih.gov/pubmed/28505185
http://dx.doi.org/10.1371/journal.pntd.0005620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444850/
https://www.ncbi.nlm.nih.gov/pubmed/28505185
http://dx.doi.org/10.1371/journal.pntd.0005620

Ejemplares similares